Shanghai Huiyu Biotech

Shanghai Huiyu Biotech is a clinical-stage biopharmaceutical company specializing in the development of innovative small molecule drugs through its proprietary Proteolysis Targeting Chimera (PROTAC) platform. Founded in 2018 and headquartered in Shanghai's Zhangjiang Hi-Tech Park, the company focuses on addressing high unmet medical needs in oncology and autoimmune diseases. Its lead candidate, HY-001, is a novel BTK degrader currently undergoing Phase 1 clinical trials for the treatment of various B-cell malignancies. The company's pipeline also includes several pre-clinical programs targeting the estrogen receptor and androgen receptor for solid tumors. By leveraging targeted protein degradation, Shanghai Huiyu Biotech aims to develop therapies that can overcome resistance to traditional inhibitors and target previously undruggable proteins.